Dosing of polyomavirus neutralizing antibodies

A method for treating a BK or JC polyomavirus infection in a human subject in need thereof, comprising intravenously administering to the subject a dosage of an antibody, or an antigen-binding fragment thereof, which specifically binds to a VP1 protein of the polyomavirus, wherein the dosage is between about 10 mg/kg and about 100 mg/kg,

• wherein the antibody, or antigen-binding fragment thereof, comprises
• a heavy chain variable (VH) that comprises complementary determining region (CDR) VHCDR1, VHCDR2, and VHCDR3 sequences of SEQ ID NOs:
• 6-8, respectively;
• and
• a light chain variable (VL) region that comprises VLCDR1, VLCDR2, and VLCDR3 sequences of SEQ ID NOs:
• 9-11, respectively,
• and variants thereof which specifically bind to the VP1 protein.